These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 19828561

  • 1. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
    Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV.
    Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
    Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M.
    J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
    [Abstract] [Full Text] [Related]

  • 3. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
    Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP.
    J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
    [Abstract] [Full Text] [Related]

  • 4. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao YD, Liepa AM, Peterson P, Tonato M.
    J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
    [Abstract] [Full Text] [Related]

  • 5. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D.
    J Clin Oncol; 2008 Jul 20; 26(21):3543-51. PubMed ID: 18506025
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
    Gridelli C, Rossi A, Di Maio M, Leo S, Filipazzi V, Favaretto AG, Burgio MA, Cinieri S, Bianco R, Ciardiello F, Cavanna L, Bordonaro R, Costanzo R, Sandomenico C, Gallo C, Perrone F, Morabito A.
    Clin Lung Cancer; 2014 Mar 20; 15(2):166-70. PubMed ID: 24418693
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
    Wu YL, Lu S, Cheng Y, Zhou C, Wang M, Qin S, Lu Y, Zhang Y, Zhu Y, Song X, Wang X, Barraclough H, Zhang X, Chi H, Orlando M.
    Lung Cancer; 2014 Sep 20; 85(3):401-7. PubMed ID: 25082564
    [Abstract] [Full Text] [Related]

  • 8. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
    Treat J, Bonomi P, McCleod M, Christiansen NP, Mintzer DM, Monberg MJ, Ye Z, Chen R, Obasaju CK.
    Lung Cancer; 2006 Jul 20; 53(1):77-83. PubMed ID: 16730854
    [Abstract] [Full Text] [Related]

  • 9. Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
    Novello S, Pimentel FL, Douillard JY, O'Brien M, von Pawel J, Eckardt J, Liepa AM, Simms L, Visseren-Grul C, Paz-Ares L.
    J Thorac Oncol; 2010 Oct 20; 5(10):1602-8. PubMed ID: 20808252
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M.
    J Thorac Oncol; 2013 Jul 20; 8(7):906-14. PubMed ID: 23591160
    [Abstract] [Full Text] [Related]

  • 11. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
    Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA.
    Oncologist; 2009 Mar 20; 14(3):253-63. PubMed ID: 19221167
    [Abstract] [Full Text] [Related]

  • 12. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.
    Clin Transl Oncol; 2017 Mar 20; 19(3):317-325. PubMed ID: 27492015
    [Abstract] [Full Text] [Related]

  • 13. PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Reck M, Paz-Ares LG, de Marinis F, Molinier O, Sahoo TP, Laack E, John W, Zimmermann AH, Visseren-Grul C, Gridelli C.
    J Thorac Oncol; 2014 Feb 20; 9(2):205-13. PubMed ID: 24419418
    [Abstract] [Full Text] [Related]

  • 14. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G, Gruppo Ocologico Italia Meridionale.
    Lung Cancer; 2003 Feb 20; 39(2):179-89. PubMed ID: 12581571
    [Abstract] [Full Text] [Related]

  • 15. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
    Li CH, Liu MY, Liu W, Li DD, Cai L.
    Asian Pac J Cancer Prev; 2014 Feb 20; 15(2):731-6. PubMed ID: 24568487
    [Abstract] [Full Text] [Related]

  • 16. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
    Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg M, Scagliotti G.
    Clin Lung Cancer; 2012 Jan 20; 13(1):24-30. PubMed ID: 21831719
    [Abstract] [Full Text] [Related]

  • 17. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
    Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT, Scott H.
    J Thorac Oncol; 2013 Oct 20; 8(10):1255-64. PubMed ID: 24457236
    [Abstract] [Full Text] [Related]

  • 18. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
    Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA.
    Lung Cancer; 2012 May 20; 76(2):222-7. PubMed ID: 22115704
    [Abstract] [Full Text] [Related]

  • 19. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
    Huang Y, Liu Y, Zhou J, Xu N, Li B, Wu G, Fang J, Li K, Liu X, Liu W, Lu Y, Wang M, Liu W, Liang H, Zhang Y, Huang C, Wang S, Wang Y, Yu S, Chang J, Wang Z, Hu Z, Zhang L.
    Zhongguo Fei Ai Za Zhi; 2012 Oct 20; 15(10):576-82. PubMed ID: 23075681
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
    Gadgeel SM, Ruckdeschel JC, Patel BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A.
    J Thorac Oncol; 2011 May 20; 6(5):927-33. PubMed ID: 21415776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.